- Home
- SRRK vs TDS Comparison
SRRK vs TDS Comparison
Compare SRRK & TDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRRK | TDS |
|---|---|---|
| Founded | 2012 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRRK | TDS |
|---|---|---|
| Price | $45.04 | $42.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $55.40 | $53.33 |
| AVG Volume (30 Days) | ★ 1.1M | 702.3K |
| Earning Date | 03-03-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 0.38% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.05 |
| Revenue Next Year | $449.79 | $1.72 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.71 | $31.07 |
| 52 Week High | $49.82 | $47.80 |
Technical Indicators
Market Signals| Indicator | SRRK | TDS |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 35.65 |
| Support Level | $41.54 | $36.76 |
| Resistance Level | $48.29 | $42.74 |
| Average True Range (ATR) | 2.49 | 1.18 |
| MACD | -0.28 | -0.35 |
| Stochastic Oscillator | 62.43 | 20.61 |
Price Performance
Historical ComparisonAbout SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
About TDS Telephone and Data Systems Inc.
Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.